Moderna announced plans to reduce its expenses by more than $1 billion by 2027 as it transitions from its COVID-19 business. The biotech company aims to secure ten new product approvals by 2027, including vaccines for RSV and a flu-COVID combination shot. Moderna will pause or discontinue certain pipeline products, trimming its research and development spending. The company also highlighted its potential vaccines for cancer and latent viruses, which could drive revenue growth. Moderna projects 2025 revenue between $2.5 billion and $3.5 billion and expects a 25% annual growth rate as new products launch by 2026.
Category
🗞
NewsTranscript
00:00It's Benzinga, and here's what's on the block.
00:02Moderna announced plans to reduce its expenses by more than $1 billion by 2027 as it transitions
00:08from its COVID-19 business.
00:10The biotech company aims to secure 10 new product approvals by 2027, including vaccines
00:15for RSV and a flu-COVID combination shot.
00:18Moderna won't pause or discontinue certain pipeline products, trimming its research and
00:22development spending.
00:24The company also highlighted its potential vaccines for cancer and latent viruses, which
00:28could drive revenue growth.
00:30Moderna projects 2025 revenue between $2.5 billion and $3.5 billion and expects a 25
00:35percent annual growth rate as new products launch by 2026.
00:38For all things money, visit Benzinga.com.